Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
Trifirò
Gianluca
G
Morgante
Letterio
L
Tari
Michele
M
Arcoraci
Vincenzo
V
Savica
Rodolfo
R
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077465:Cabergoline; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D000077465:Cabergoline